The importance of nerve growth factor (NGF) for the development of sensory ganglia was investigated by injecting rat fetuses (16.50 days of gestation) with a single dose of anti-NGF antiserum. Four months later the treated animals showed a very large decrease in substance P- and so- matostatin-like immunoreactivities in dorsal root ganglia and skin with a lesser decrease in trigeminal ganglia. Fluoride-re- sistant acid phosphatase, substance P-, and somatostatin-like immunoreactivities were greatly decreased in the dorsal horn of the spinal cord. No change in neurotensin- and (Met)enke- phalin-like immunoreactivities was observed. The anti-NGF antiserum treatment produced a >90% decrease in the num- ber ofunmyelinated dorsal root fibers and a 35% decrease in the total number of myelinated fibers. The loss in myelinated fibers was restricted to small-diameter fibers with no change in large-diameter fibers. No change in taste bud morphology was noted, thereby refuting the proposal that anti-NGF antise- rum treatment may represent an animal model for familial dy- sautonomia. The present results indicate that NGF is a neces- sary requirement for the normal development of a significant population of prenatal rat dorsal root ganglion cells.
Peripheral benzodiazepine (BDZ) receptor (PBR) and diazepam-binding inhibitor/acyl-CoA-binding protein (DBI/ACBP) characterized as a ligand at central BDZ receptors, at PBR with involvement in the regulation of steroidogenesis, and as an intracellular acyl-CoA transporter, are both known to interact with BDZ in adult systems. We investigated their expression after prenatal exposure to BDZ. Diazepam (1.25 mg/kg per day s.c.) was administered to time-pregnant Long Evans rats from gestational day (GD) 14 to 20. Expression of mRNAs encoding for PBR and for DBI/ACBP was studied in the same animals with (33)P-labeled 60 mer oligonucleotides (oligos) by in situ hybridization at GD20, and with (32)P-labeled oligos by Northern blot in steroidogenic and immune organs at postnatal day (PN) 14 and in adult offspring. Prenatal diazepam increased DBI/ACBP mRNA expression in male fetal adrenal and in fetal and PN14 testis. Thymus exhibited increased DBI/ACBP mRNA in male fetuses and in adult female offspring, and reduced organ weight at PN14 in both sexes. In female spleen, an increase in DBI/ACBP mRNA and a decrease in PBR mRNA was seen at PN14. Apart from the finding in spleen, no drug-induced changes in PBR mRNA were observed. The effects of prenatal diazepam were superimposed on treatment-independent sex differences in DBI/ACBP mRNA and PBR mRNA expression. Our data indicate that expression of DBI/ACBP mRNA in steroidogenic and immune organs can be affected by exposure to BDZ during ontogeny, while PBR mRNA expression appears to be less sensitive. They further reveal marked sex differences in the developmental patterns of the two proteins during pre- and postpubertal ontogeny.
Background: Salbutamol has been shown to mediate anabolic effects after intravenous administration. However, the mechanism responsible for the anabolic actions of salbutamol remains unknown. Aim: To investigate the potential mechanism by which salbutamol mediates anabolic effects in vitro. Methods: The potential androgenic activity of salbutamol was investigated in vitro by the A-Screen assay that measures androgen-dependent inhibition of proliferation of the androgen receptor (AR)-positive human mammary carcinoma cell line, MCF7-AR1. Results: The assay was validated with three known androgens; methyltrienolone (R1881), 5α-dihydrotestosterone (DHT) and danazol. IC 50 values of R1881, DHT and danazol, 4.41×10 −11 , 4.44×10 −11 and 1.08×10 −8 M, respectively, were in the ranges known from earlier studies. Our results demonstrate that salbutamol exhibits androgenic activity, with an IC 50 value of 8.93×10 −6 M. Anti-estrogenic or cytotoxic effects, which might have interfered with the assay, were excluded by additional experiments on wild-type MCF7 and MCF7-AR1 cells, respectively. Conclusion: These data indicate that salbutamol exerts anabolic effects through androgen receptor agonistic activity in vitro.
Abstract: Treatment of pregnant Long Evans rats with benzodiazepines was found to cause alterations in cellular immune responses in their offspring. We now report on changes in interleukin‐1 (IL‐1) and IL‐2 secretion which were analyzed in rats from birth until 12 weeks. Time‐pregnant rats were treated with diazepam (1.25 mg/kg/day subcutaneously) from gestational day 14 to 20. Lipopolysaccharide‐stimulated release of macrophage‐derived IL‐1 by spleen cells, determined on D10.G4.1 cells, remained in the control range during the preweaning period (postnatal day 6–28), then decreased in prenatally diazepam‐exposed offspring, significantly in males during the postweaning period (postnatal day 34–61) and in both sexes in adults (postnatal day 62–83). Concanavalin A‐stimulated release of T lymphocyte‐derived IL‐2 from spleen cells, determined on CTLL‐2 cells, was reduced in male and female offspring during preweaning (postnatal day 3–28) and postweaning (postnatal day 33–55) periods and normalized in adulthood (postnatal day 60–84). The percentage of IL‐2 receptor expressing (CD25+) cells was unaffected. From these and our earlier data it is evident that prenatal exposure to low doses of benzodiazepines can result in long‐lasting alterations of the cytokine network, as indicated by reduced release of TNF‐α, IL‐1, IL‐6, IL‐2 and interferon‐γ. The concomitant reduction of peripheral type benzodiazepine receptors on macrophages is discussed as a possible link between prenatal treatment and disturbed function.